Back to Stress
SupplementModerate evidenceStress

Silexan lavender (oral WS 1265)

Standardised oral lavender oil preparation (Lasea), registered in DE/AT for subthreshold and generalised anxiety with multiple RCTs and head-to-head non-inferiority to lorazepam.

Why

Silexan (WS 1265) is a patented standardised oral preparation of Lavandula angustifolia essential oil, registered as the medicinal product Lasea in Germany and Austria. Distinct from inhaled or topical lavender aromatherapy and from the existing lavender catalogue entry. Multiple RCTs (Kasper 2010 onwards) document significant reductions in subthreshold and generalised anxiety, with a head-to-head non-inferiority RCT against lorazepam in GAD (Woelk 2010). The Möller 2019 meta-analysis confirmed effect on Hamilton Anxiety Scale across the GAD trial set.

How it works

Linalool and linalyl acetate (the principal monoterpenoid actives) reduce presynaptic calcium influx in serotonergic and noradrenergic neurons via voltage-dependent calcium channel modulation. Non-benzodiazepine GABAergic involvement is proposed but pharmacologically distinct.

Expected onset · Effects emerge over 1–2 weeks; full effect by 6–10 weeks

How to take

Dosage

Silexan (Lasea): 80 mg once daily (one soft gelatine capsule).

Timing

Once daily, morning or evening as preferred

On the label

Specifically 'Silexan' or 'WS 1265' or 'Lasea': the registered medicinal preparation. Generic lavender oil capsules are not pharmacologically equivalent.

Ideal for

Adults with subthreshold anxiety, mixed anxiety-depression, or generalised anxiety disorder seeking a non-benzodiazepine, non-SSRI option, particularly when pharmaceutical sedation is unwanted.

Safety

Mild gastric reflux and 'lavender burp' aftertaste are the most common adverse effects. No sedation, no withdrawal on discontinuation, no documented dependence potential, distinct from benzodiazepines. Generally well tolerated. Avoid in pregnancy (limited data) and breastfeeding. No significant drug interactions documented at the registered 80 mg dose.

Evidence

At a glance

Woelk 2010 Phytomedicine head-to-head non-inferiority RCT (n=77 GAD): Silexan 80 mg/day non-inferior to lorazepam 0.5 mg/day on HAM-A score over 6 weeks, with no sedation and no dependence signal. Möller 2019 meta-analysis confirmed effect on Hamilton Anxiety Scale across the trial set. Registered as the medicinal product Lasea in DE/AT: a clinical-grade regulatory anchor.

Where to get it

Shop Silexan lavender (oral WS 1265) on Amazon

Sponsored · As an Amazon Associate, Healicus earns from qualifying purchases.